Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin Added to Metformin in Type 2 Diabetes
NCT02926950Phase 3Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sotagliflozin + Metformin with Placebo + Metformin (2 arms). Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started Nov 2016; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02926950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926950.